Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Parenchymal splenic metastasis is an independent negative predictor of overall survival in advanced ovarian, fallopian tube, and primary peritoneal cancer.

Tanner EJ, Long KC, Feffer JB, Leitao MM Jr, Abu-Rustum NR, Barakat RR, Chi DS, Gardner GJ.

Gynecol Oncol. 2013 Jan;128(1):28-33. doi: 10.1016/j.ygyno.2012.09.019. Epub 2012 Sep 25.

PMID:
23017819
2.

Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.

Luyckx M, Leblanc E, Filleron T, Morice P, Darai E, Classe JM, Ferron G, Stoeckle E, Pomel C, Vinet B, Chereau E, Bergzoll C, Querleu D.

Int J Gynecol Cancer. 2012 Oct;22(8):1337-43.

PMID:
22964527
3.

The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Zivanovic O, Eisenhauer EL, Zhou Q, Iasonos A, Sabbatini P, Sonoda Y, Abu-Rustum NR, Barakat RR, Chi DS.

Gynecol Oncol. 2008 Feb;108(2):287-92. Epub 2007 Nov 13.

PMID:
17996927
5.

International Federation of gynecology and obstetrics staging classification for cancer of the ovary, fallopian tube, and peritoneum: estimation of survival in patients with node-positive epithelial ovarian cancer.

Pereira A, Pérez-Medina T, Magrina JF, Magtibay PM, Rodríguez-Tapia A, Peregrin I, Mendizabal E, Ortiz-Quintana L.

Int J Gynecol Cancer. 2015 Jan;25(1):49-54. doi: 10.1097/IGC.0000000000000316.

PMID:
25405578
6.

Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.

Esselen KM, Rodriguez N, Growdon W, Krasner C, Horowitz NS, Campos S.

Gynecol Oncol. 2012 Oct;127(1):51-4. doi: 10.1016/j.ygyno.2012.05.026. Epub 2012 May 30.

PMID:
22659193
7.

Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas.

Usach I, Blansit K, Chen LM, Ueda S, Brooks R, Kapp DS, Chan JK.

Am J Obstet Gynecol. 2015 Feb;212(2):188.e1-6. doi: 10.1016/j.ajog.2014.08.016. Epub 2014 Aug 18.

PMID:
25149685
8.

Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer.

Black D, Iasonos A, Ahmed H, Chi DS, Barakat RR, Abu-Rustum NR.

Gynecol Oncol. 2007 Oct;107(1):66-70. Epub 2007 Jul 5.

PMID:
17614125
9.

Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series.

Shih KK, Chi DS, Barakat RR, Leitao MM Jr.

Gynecol Oncol. 2010 May;117(2):330-5. doi: 10.1016/j.ygyno.2010.01.046. Epub 2010 Feb 26.

PMID:
20189234
10.

Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.

Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY.

Gynecol Oncol. 1999 Mar;72(3):278-87.

PMID:
10053096
11.

An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).

Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, Levine DA, Gardner GJ, Abu-Rustum NR, Barakat RR.

Gynecol Oncol. 2012 Jan;124(1):10-4. doi: 10.1016/j.ygyno.2011.08.014. Epub 2011 Sep 13.

PMID:
21917306
12.

Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Shih KK, Chi DS, Barakat RR, Leitao MM Jr.

Gynecol Oncol. 2010 Mar;116(3):364-9. doi: 10.1016/j.ygyno.2009.10.047. Epub 2009 Nov 7.

PMID:
19897231
13.

Restaging and Survival Analysis of 4036 Ovarian Cancer Patients According to the 2013 FIGO Classification for Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.

Rosendahl M, Høgdall CK, Mosgaard BJ.

Int J Gynecol Cancer. 2016 May;26(4):680-7. doi: 10.1097/IGC.0000000000000675.

PMID:
26937751
14.

Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG).

Dahm-Kähler P, Borgfeldt C, Holmberg E, Staf C, Falconer H, Bjurberg M, Kjölhede P, Rosenberg P, Stålberg K, Högberg T, Åvall-Lundqvist E.

Gynecol Oncol. 2017 Jan;144(1):167-173. doi: 10.1016/j.ygyno.2016.10.039. Epub 2016 Nov 3.

PMID:
27817932
15.

The influence of splenic metastases on survival in FIGO stage IIIC epithelial ovarian cancer.

Ayhan A, Al RA, Baykal C, Demirtas E, Ayhan A, Yüce K.

Int J Gynecol Cancer. 2004 Jan-Feb;14(1):51-6.

PMID:
14764029
16.

[Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].

Ma Y, Li Y, Cui H, Liang XD, Tang ZJ, Li XP, Zhao Y, Wei LH.

Zhonghua Fu Chan Ke Za Zhi. 2012 May;47(5):355-60. Chinese.

PMID:
22883524
17.

Recurrence patterns of advanced ovarian, fallopian tube, and peritoneal cancers after complete cytoreduction during interval debulking surgery.

Usami T, Kato K, Taniguchi T, Abe A, Nomura H, Yamamoto A, Matoda M, Okamoto S, Kondo E, Omatsu K, Kawamata Y, Takeshima N.

Int J Gynecol Cancer. 2014 Jul;24(6):991-6. doi: 10.1097/IGC.0000000000000142.

PMID:
24905612
18.

Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.

Chi DS, Franklin CC, Levine DA, Akselrod F, Sabbatini P, Jarnagin WR, DeMatteo R, Poynor EA, Abu-Rustum NR, Barakat RR.

Gynecol Oncol. 2004 Sep;94(3):650-4.

PMID:
15350354
19.

Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer.

Chang SJ, Bristow RE, Ryu HS.

Gynecol Oncol. 2012 Sep;126(3):381-6. doi: 10.1016/j.ygyno.2012.05.014. Epub 2012 May 18.

PMID:
22609747
20.

Characteristics and management of diaphragm involvement in patients with primary advanced-stage ovarian, fallopian tube, or peritoneal cancer.

Einenkel J, Ott R, Handzel R, Braumann UD, Horn LC.

Int J Gynecol Cancer. 2009 Oct;19(7):1288-97. doi: 10.1111/IGC.0b013e3181a3a833.

PMID:
19823067

Supplemental Content

Support Center